Clone:
REA769
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC, MC
Alternative names:
B3GAT1, GLCATP, GLCUATP, HNK-1, Leu-7, NK-1

Extended validation for CD57 Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA769
HNK-1++
QA17A04++
NK-1+
TB01+
TB03++
Cells were incubated with an excess of purified unconjugated CD57 (REA769) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD57. Human peripheral blood mononuclear cells (PBMCs) were stained with CD57 antibodies and with a suitable counterstaining. As a control, CD57 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD57. Human peripheral blood mononuclear cells (PBMCs) were stained with CD57 antibodies and with a suitable counterstaining. As a control, CD57 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD57. Human peripheral blood mononuclear cells (PBMCs) were stained with CD57 antibodies and with a suitable counterstaining. As a control, CD57 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD57. Human peripheral blood mononuclear cells (PBMCs) were stained with CD57 antibodies and with a suitable counterstaining. As a control, CD57 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD57. Human peripheral blood mononuclear cells (PBMCs) were stained with CD57 antibodies and with a suitable counterstaining. As a control, CD57 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD57. Human peripheral blood mononuclear cells (PBMCs) were stained with CD57 antibodies and with a suitable counterstaining. As a control, CD57 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD57. Human peripheral blood mononuclear cells (PBMCs) were stained with CD57 antibodies and with a suitable counterstaining. As a control, CD57 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD57 (REA769). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD57 (REA769). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD57 (REA769). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD57 Antibody, anti-human, REAfinity™

Overview

Clone REA769 recognizes the human CD57 antigen. CD57, also known as HNK-1 or Leu-7, is an antigenic oligosaccharide moiety detected on extracellular proteins of certain cell types. In blood, CD57 is found on 15–20% of mononuclear cells, including subsets of NK and T cells, though not on erythrocytes, monocytes, granulocytes, or platelets. Also, CD57 expression can be found on a variety of neural cell types. CD57 has been shown to be expressed on late stage effector CD8
+
T cells. The frequency of CD57
+
T lymphocytes is raised in a variety of diseases. CD57 expression is also increased on chronically activated CD8
+
T cells in persistent viral infections, such as HIV.
Additional information: Clone REA769 displays negligible binding to Fc receptors.

Alternative names

B3GAT1, GLCATP, GLCUATP, HNK-1, Leu-7, NK-1

Detailed product information

Technical specifications

CloneREA769
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD57
Alternative names of antigenB3GAT1, GLCATP, GLCUATP, HNK-1, Leu-7, NK-1
Molecular mass of antigen [kDa]38
Distribution of antigenT cells, B cells, NK cells, CNS cells, ES and iPS cells, brain
Entrez Gene ID27087
RRIDAB_2658748, AB_2658749, AB_2658750, AB_2658751, AB_2658752, AB_2658753, AB_2658754, AB_2658755, AB_2658756, AB_2819660, AB_2658747

Resources for CD57 Antibody, anti-human, REAfinity™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD57 Antibody, anti-human, REAfinity™

Publications

  1. Mechtersheimer, G. et al. (1991) Expression of the natural killer cell-associated antigens CD56 and CD57 in human neural and striated muscle cells and in their tumors. Cancer Res. 51: 1300-1307
  2. Dupuy d'Angeac, A. et al. (1993)
    Increased percentage of CD3
    +
    , CD57
    +
    lymphocytes in patients with rheumatoid arthritis. Correlation with duration of disease.
    Arthritis Rheum. 36: 608-612
  3. Ong, E. et al. (2002)
    Biosynthesis of HNK-1 glycans on O-linked oligosaccharides attached to the neural cell adhesion molecule (NCAM): the requirement for core 2 β1,6-
    N
    -acetylglucosaminyltransferase and the muscle-specific domain in NCAM.
    J. Biol. Chem. 277: 18182-18190
  4. Brenchley, J. M. et al. (2003)
    Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8
    +
    T cells.
    Blood 101: 2711-2720
  5. Palmer, B. E. et al. (2005)
    Functional and phenotypic characterization of CD57
    +
    CD4
    +
    T cells and their association with HIV-1-induced T cell dysfunction.
    J. Immunol. 175: 8415-8423

Related products for
CD57 Antibody, anti-human, REAfinity™

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?